 FOSTER CITY, Calif.--BUSINESS WIRE--Mirum Pharmaceuticals, Inc. Nasdaq: MIRM, a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced the pricing of its previously announced underwritten public offering of 3,750,000 shares of its common stock at a price to the public of 20.00 per share. The gross proceeds to Mirum from the offering, before deducting underwriting discounts and c 